China’s patent linkage plan in serious doubt
Proposals to introduce a US-style Orange Book system seem to have been shelved, showing pharma innovators’ limited influence in the country
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Register now
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.
Subscribe now